Astellas Pharma’s Vernakalant For Atrial Fibrillation Goes Before FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Cardiovascular and Renal Drugs Advisory Committee considers Astellas’ NDA re-submission for the indication Dec. 11.